| Michael E Weigle, OD | |
|
2127 Bluestone Dr, Suite 201, Saint Charles, MO 63303-6709 | |
| (636) 947-0207 | |
| (636) 947-5996 |
| Full Name | Michael E Weigle |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 32 Years |
| Location | 2127 Bluestone Dr, Saint Charles, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295715852 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | TO3032 (Missouri) | Primary |
| Provider Name | The Optical Shop Of West Clay Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073658290 PECOS PAC ID: 2668591306 Enrollment ID: O20120109000434 |
News Archive
Patients with bipolar disorder are more likely to have impaired clinical insight after, rather than before, manic exacerbations, researchers report.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
Multiple sclerosis is an autoimmune disease. The defense system that usually protects patients from external aggression turns on its own cells and attacks them for reasons that are not yet known.
For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD.
This is what we have all been working towards and fighting for, says Daniel Paul Perez, co-founder, president and CEO of the FSH Society and a 48-year-old patient with facioscapulohumeral muscular dystrophy (FSHD), applauding the researchers whose study on yesterday's ScienceXpress, the journal Science's online advanced edition, pinpoints for the first time the exact genetic mechanism triggering FSHD, the most common muscular dystrophy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael E Weigle, OD 2127 Bluestone Dr, Suite 201, Saint Charles, MO 63303-6709 Ph: (636) 947-0207 | Michael E Weigle, OD 2127 Bluestone Dr, Suite 201, Saint Charles, MO 63303-6709 Ph: (636) 947-0207 |
News Archive
Patients with bipolar disorder are more likely to have impaired clinical insight after, rather than before, manic exacerbations, researchers report.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
Multiple sclerosis is an autoimmune disease. The defense system that usually protects patients from external aggression turns on its own cells and attacks them for reasons that are not yet known.
For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD.
This is what we have all been working towards and fighting for, says Daniel Paul Perez, co-founder, president and CEO of the FSH Society and a 48-year-old patient with facioscapulohumeral muscular dystrophy (FSHD), applauding the researchers whose study on yesterday's ScienceXpress, the journal Science's online advanced edition, pinpoints for the first time the exact genetic mechanism triggering FSHD, the most common muscular dystrophy.
› Verified 7 days ago
Clarkson Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 2121 Zumbehl Rd, Saint Charles, MO 63303 Phone: 636-200-4393 Fax: 636-949-2914 | |
Dr. Kerianne Phillips Sayre, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2897 Veterans Memorial Pkwy, Saint Charles, MO 63303 Phone: 636-724-4797 Fax: 636-724-4568 | |
Kristin N Doerfler, Optometrist Medicare: Medicare Enrolled Practice Location: 1384 S 5th St, Saint Charles, MO 63301 Phone: 636-946-9242 Fax: 636-946-4903 | |
Crown Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1944 Zumbehl Rd, Saint Charles, MO 63303 Phone: 636-916-5367 Fax: 800-432-6004 | |
Midwest Eye Associates, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 1384 S 5th St, Saint Charles, MO 63301 Phone: 636-946-9242 Fax: 636-946-4903 | |
Molly Lamprecht, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1529 S Old Highway 94 Ste 120, Saint Charles, MO 63303 Phone: 636-949-2900 Fax: 866-636-1311 | |
Bogey Hills Vision Center Optometrist Medicare: Medicare Enrolled Practice Location: 2035 Zumbehl Rd, Saint Charles, MO 63303 Phone: 636-946-1176 Fax: 636-946-1533 |